Biomarkers Predict Long-Term Kidney Function After Acute Kidney Injury
By LabMedica International staff writers Posted on 27 Oct 2021 |
Image: Plasma biomarkers measured three months after hospitalization demonstrate utility in assessing AKI patients for long-term CKD risk (Photo courtesy of National Kidney Foundation)
Acute kidney injury (AKI), previously called acute renal failure (ARF), is a sudden decrease in kidney function that develops within seven days, as shown by an increase in serum creatinine or a decrease in urine output, or both.
AKI may lead to a number of complications, including metabolic acidosis, high potassium levels, uremia, changes in body fluid balance, and effects on other organ systems, including death. People who have experienced AKI are at increased risk of developing chronic kidney disease in the future.
Medical Scientists at the Royal Derby Hospital (Derby, UK) and their colleagues evaluated a number of new blood tests in people who have had AKI, aiming to improve the ability to assess the risk of new or progressive kidney disease. Among a panel of 11 biomarkers tested, a combination of the most promising were identified, comprising Soluble Tumor Necrosis Factor Receptor (sTNFR)1, sTNFR2, cystatin C and eGFR. A total of 500 patients were studied that included adults from a single clinical center who developed AKI, and survived until three years after the hospitalization during which AKI occurred. Participants included those with and without pre-existing chronic kidney diseases (CKD).
The investigators reported that soluble tumor necrosis factor receptor 1 (sTNFR1), sTNFR2, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), three-month eGFR and urine albumin:creatinine ratio (ACR) were independently associated with kidney disease progression and were more important than AKI severity or duration. A multivariable model containing sTNFR1, sTNFR2, cystatin C and eGFR discriminated between those with and without kidney disease progression (AUC 0.79, 95% CI 0.7-0.83). Optimizing the cut-point to maximize utility as a ‘rule-out’ test to identify those at low risk increased the sensitivity of the model to 95% and its negative predictive value to 92%.
The authors concluded that a panel of plasma biomarkers measured 3-months after discharge from a hospitalization complicated by AKI provides potential opportunity to identify patients who are at very low risk of incident or worsening CKD. Further study is required to determine its clinical utility through independent prospective validation. The study was published on October 12, 2021 in the American Journal of Kidney Diseases.
Related Links:
Royal Derby Hospital
AKI may lead to a number of complications, including metabolic acidosis, high potassium levels, uremia, changes in body fluid balance, and effects on other organ systems, including death. People who have experienced AKI are at increased risk of developing chronic kidney disease in the future.
Medical Scientists at the Royal Derby Hospital (Derby, UK) and their colleagues evaluated a number of new blood tests in people who have had AKI, aiming to improve the ability to assess the risk of new or progressive kidney disease. Among a panel of 11 biomarkers tested, a combination of the most promising were identified, comprising Soluble Tumor Necrosis Factor Receptor (sTNFR)1, sTNFR2, cystatin C and eGFR. A total of 500 patients were studied that included adults from a single clinical center who developed AKI, and survived until three years after the hospitalization during which AKI occurred. Participants included those with and without pre-existing chronic kidney diseases (CKD).
The investigators reported that soluble tumor necrosis factor receptor 1 (sTNFR1), sTNFR2, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), three-month eGFR and urine albumin:creatinine ratio (ACR) were independently associated with kidney disease progression and were more important than AKI severity or duration. A multivariable model containing sTNFR1, sTNFR2, cystatin C and eGFR discriminated between those with and without kidney disease progression (AUC 0.79, 95% CI 0.7-0.83). Optimizing the cut-point to maximize utility as a ‘rule-out’ test to identify those at low risk increased the sensitivity of the model to 95% and its negative predictive value to 92%.
The authors concluded that a panel of plasma biomarkers measured 3-months after discharge from a hospitalization complicated by AKI provides potential opportunity to identify patients who are at very low risk of incident or worsening CKD. Further study is required to determine its clinical utility through independent prospective validation. The study was published on October 12, 2021 in the American Journal of Kidney Diseases.
Related Links:
Royal Derby Hospital
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines